The scale of label expansion in the two years to mid-2026 has been rapid. According to IQVIA’s Outlook for Obesity in 2026, the FDA approved semaglutide for obstructive sleep apnoea in December 2024, metabolic dysfunction-associated steatohepatitis with moderate-to-advanced fibrosis in August 2025, and chronic kidney disease in patients with type 2 diabetes in January 2025, with the latter indication also approved by the EMA. Tirzepatide received FDA approval to reduce cardiovascular risk in patients with type 2 diabetes in early 2026. Clinical reporting at the American Diabetes Association 2026 Scientific Sessions, covered by the American Journal of Managed Care in June 2026, confirmed that GLP-1 receptor agonists are being actively investigated for heart failure with preserved ejection fraction, where early data have shown clinically meaningful cardiovascular benefit compared with older therapies, as well as for musculoskeletal outcomes and further emerging metabolic indications. The Prime Therapeutics GLP-1 Pipeline Update series, published throughout 2025 and 2026, has systematically tracked this progression through successive regulatory decisions.
Indication Expansion as a Reimbursement and Formulary Strategy
For European payers, the challenge created by indication expansion is not merely clinical; it is structural. A product initially assessed and priced for weight management may present a significantly different cost-effectiveness case to a national HTA body once cardiovascular or renal indications are approved. The Haute Autorité de Santé, the National Institute for Health and Care Excellence, and their counterparts in other European markets will each need to adjudicate whether a new indication submission represents a material clinical advance over existing standard of care, and whether the incremental benefit justifies the price premium. Germany's Gemeinsamer Bundesausschuss, which has excluded GLP-1 therapies from statutory coverage for the obesity indication, will nonetheless conduct early benefit assessments for each new indication under the AMNOG framework, creating a distinct assessment track for cardiovascular and metabolic indications that may produce different outcomes from the obesity exclusion.
Market access teams planning multi-indication launches need to consider not only the clinical evidence strategy but also the sequencing of submissions, the design of the economic model, and the management of reference price implications across markets where the product is already on the formulary under a different indication. Real-world evidence programmes have become an important tool for building post-authorisation evidence packages that answer the specific clinical questions national payers are asking, including long-term outcomes, health system resource utilisation, and the comorbidity burden in the actual treated population. Digital health platforms and patient registry infrastructure are increasingly positioned as data generation partners in the market access process.
Obesity Therapies Europe 2027 brings together pharmaceutical manufacturers, HTA bodies, payers, outcomes researchers, and digital health providers to examine how multi-indication development and access strategies are being built, tested, and refined in a market that is still establishing the evidence and pricing frameworks for each new label.
